As the activation of the cGAS/STING pathway in the tumor microenvironment can induce the effective cross-priming of tumor-specific antigens and promote the infiltration of effector T cells (45), STING agonists have been developed to simulate this activation in order to enhance the anticancer effect. Here, STING1 is linked to neoplasm.